Parikh 2007.

Methods	Randomised controlled trial
Participants	121 VLBW infants < 3 days old (one infant was withdrawn on day of randomisation and not included in any analyses) "Critically ill" infants and infants with biochemical evidence of hepatic insufficiency were not eligible for inclusion
Interventions	Fluconazole (N = 60) 6 mg/kg every third day for the first week after birth, then every day until four weeks versus "sugar solution" placebo (N = 60). Administered intravenously and then enterally when tolerated
Outcomes	Fungal colonisation and invasive infection Emergence of fluconazole resistance Adverse drug reactions Death prior to hospital discharge
Notes	Most invasive fungal infection was due to non‐albicans Candida species (mainly C. glabrata) which were relatively less susceptible to fluconazole. Setting: KEM Hospital and Seth GS Medical College, Mumbai; 2003 to 2004
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment (selection bias)	Low risk	Sealed opaque envelopes
Blinding (performance bias and detection bias) All outcomes	Low risk	Placebo‐controlled
Blinding of participants and personnel (performance bias) All outcomes	Low risk	Placebo‐controlled
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Placebo‐controlled
Incomplete outcome data (attrition bias) All outcomes	Low risk	Near‐complete follow‐up